創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
21/10/12 GEM256 Stem cell repairing Osteoarthritis Intraーarticular Peptide Preclinical Synthetic novel PEDF-derived short peptide that stimulates cartilage regeneration morphology and pain relief efficacy (MIA-induced model, medial meniscal transection (MMT) model).
Long patent protection.Available for licensing globally.
問合せ
21/10/12 GEM255 Stem cell repairing Neurotropic keratitis Topical (eye drop) Peptide Phase 1 Synthetic novel neurotrophic PEDF-derived short peptide that stimulates wound healing and corneal repair. Effectively regenerate healthy limbus after extensive limbal layer removal (Rabbit Model)
Long patent protection.Available for licensing globally.
問合せ
21/10/12 GEM254 Stem cell repairing Dry eye syndrome Topical (eye drop) Peptide Phase 2 Synthetic PEDF-derived short peptide to stimulate proliferation and differentiation of corneal limbal stem cells to speed up cornea repair process. Repair severe cornea damages for patients
lacking treatment options.
The Phase 2 studies demonstrated that GEM254 is safe, effective, and the results are reproducible.
Long patent protection.
Available for licensing globally excluding China.
問合せ
21/09/17 GEM253 Influenza Virus-Neutralizing antibody Influenza i.v. Antibody Preclinical Neutralizing activity against Influenza virus, human H1N1, H2N2, H3N2, H5N1, and avian H3N8.
Passive immunization with the pan-neutralizing antibody enables to effectively prevent or treat influenza even in the event of an antigenic shift, as well as an antigenic drift.
問合せ
21/09/14 GEM252 Cultured skin stem cells autografts Spinal cord injury Trans-plant into spinal cord (Auto-logus) Cell therapy Clinical application finished The Skin stem cells cultured in serum-free medium express Nestin, CD73, and GDNF. They showed no tumorigenicity in carcinogenicity test. Autologous transplantation for patients with spinal cord injury was performed with intraspinal administration via lumbar puncture. A most aggressive result was a case which a man with 2.5years paralysis of lower limbs by Th3 site injury, who recovered to the level of walking after receiving 2 times. 問合せ
21/09/08 GEM251 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene AKI(acute kidney injury), Heart failure, Stroke i.v. Nucleic acid Discovery/ Preclinical Same as GEM248 問合せ
21/09/08 GEM250 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Drug-induced alopecia Topical Nucleic acid Discovery Same as GEM248 問合せ
21/09/08 GEM249 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Sensorineural Hearing Loss Topical Nucleic acid Discovery Same as GEM248 問合せ
21/09/08 GEM248 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene ALS(C9orf72) Intraーmedullary Nucleic acid Discovery Suppression of p53 expression may reduce the tissue damage and enhance tissue repair in several disease conditions. It inhibits p53 expression better than the competitor compound in cultured cell, and is therefore expected to be highly effective in clinical practice. 問合せ
21/08/25 GEM247 Activation of progenitor and endothelial progenitor cells Chronic limb threatening ischemia Injection and device Regenerative therapy Clinical Regenerative therapy for vascular disease promotes new vessel growth. Excellent clinical results include pain relief, wound healing, hemodynamic improvement, new collaterals visible on angiography, biochemical support for mechanism of action, and limb salvage. 問合せ